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reference measure) and one ﬁngerstick analyzed by the Hemochron POC device. 
Consistent with published FDA recommendations, the previous standard QA analysis 
included linear regression, correlation and Bland Altman analysis. The novel QA 
analysis features thorough descriptive analysis and a validated method to estimate 
when INR measures lead to the same clinical decision. RESULTS: 1,666 paired INRs 
were collected. Standard QA analysis deemed the Hemochron device acceptable. 
Notably, the correlation between the Hemochron and laboratory was 0.9. Our novel 
analysis revealed the Hemochron never reported seven INR values: 2.1, 2.7, 3.1, 3.5, 
3.8, 4.1, and 4.4. Furthermore, the Hemochron systematically inﬂated lower INRs 
and deﬂated higher values. Consequently, 30% (503 / 1,666) of clinical decisions were 
predicted to differ using the Hemochron. The laboratory was nearly twice as likely to 
report an INR below the target range (RR: 1.9, 95% CI: 1.7–2.1) than the Hemo-
chron. CONCLUSIONS: Standard QA analysis missed clinically important deﬁcien-
cies in the Hemochron device. Our novel analysis revealed the Hemochron does not 
report all INR values and leads to incorrect clinical decisions an unacceptably large 
proportion of times. The Hemochron device has been replaced in our institution. QA 
analyses should be reported in explicitly clinical terms so decision-makers understand 
the implications to patient care.
PCV148
RELATIONSHIP BETWEEN VENOUS THROMBOEMBOLISM AND 
HOSPITAL QUALITY
Baser O1, Akin C2, Wang L3, Dysinger A3
1STATinMED Research / University of Michigan, Ann Arbor, MI, USA, 2STATinMED 
Research / Brigham and Women’s Hospital, Ann Arbor, MI, USA, 3STATinMED Research, 
Ann Arbor, MI, USA
OBJECTIVES: To examine the association between venous thromboembolism (VTE) 
events and hospital quality for patients who underwent major orthopedic surgery. 
METHODS: Based on 2005–2007 national Medicare claims, all patients who under-
went major orthopedic surgery were identiﬁed. Rates for patients who had a VTE 
event during their initial hospitalization were calculated. By using the CompQualTM 
scoring algorithm, every provider in the Medicare dataset was ranked according to 
their quality. This algorithm, with an empirical Bayesian approach, combines volume 
and mortality rate of hospitals to create an index score. Hospitals are ranked in 
quintiles. Logistic regression was used to see the effect of quality on VTE event rates. 
RESULTS: We obtained a sample that included 642 patients in the pulmonary embo-
lism (PE) only group, 1950 patients in the deep vein thrombosis (DVT) only group, 
and 153 patients in the both PE and DVT group. After controlling for patients’ 
demographic and clinical factors, VTE events in low quality hospitals were almost 2.5 
times higher than VTE events in high quality hospitals (p = 0.000). CONCLUSIONS: 
Any policy implementation that would decrease the variation in hospital quality would 
have a direct effect on the rates of VTE events.
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OBJECTIVES: To determine association of recommended pharmacotherapy in CHF 
with geographic variation in clinical outcomes. METHODS: Veterans with at least 
one outpatient visit with CHF diagnosis from FY2000–2001 were included in a 
cohort. Patients with non-utilization of VA for two years were excluded. Twenty-two 
Veteran Integrated Service Network (VISNs) of the VA were geographic units of 
analyses. Outcomes evaluated were: death, all-cause hospitalization and heart failure 
hospitalization. Recommended pharmacotherapy was measured by use of ACE inhibi-
tors, ARBs and Beta-blockers. Follow up period was one year post index date of CHF 
diagnosis. We accounted for patient factors (gender, race, age, co-morbidities, severity 
of illness, co-medications, adherence) and process of care measures (prescription of 
recommended pharmacotherapy). Multivariate logistic regression models were used 
to calculate observed-to-expected (O/E) ratios across VISNs. Separate models were 
constructed accounting for patient factors, process of care measures and structure 
(VISNs). We ranked the outliers and interpreted, in context of, the quality of phar-
maceutical care provided. RESULTS: We analyzed 125,239 CHF cases with enough 
power to detect differences across VISNs. About 60% patients were on ACE inhibi-
tors, 8% on ARBs and 49% on Beta Blockers. Factor of variance in prescription rates 
ranged from 1.11 to 2.79. Strong correlation was observed between prescription rates 
and outcome rates (−0.48 to −0.54). c-indexes for all the models were above 0.7. 
Change in the outlier status, from the model containing patient factors versus the 
model with patient factors and process of care factors, indicated change in the quality 
of pharmaceutical care provided by the VISNs. CONCLUSIONS: In 1998, VA imple-
mented Quality Enhancement Research Initiative (QUERI) to systemize quality 
improvement. During FY2000–02, signiﬁcant variations were observed in prescription 
and outcome rates, despite efforts to synchronize quality of care. Differential prescrip-
tion rates and differential adherence rates led to the variations in the outcomes.
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OBJECTIVES: To assess the utilization of secondary preventive medications after an 
acute myocardial infarction (AMI) in a state Medicaid population. METHODS: The 
study was a retrospective cohort analysis using a state Medicaid claims database. The 
study cohort was identiﬁed based on inpatient claims for discharges with either a 
primary or secondary diagnosis code for AMI (ICD-9 code: 410.XX) between January 
1, 2002 and December 31, 2006. The study cohort was restricted to patients who 
were < 65 years old and were enrolled in the traditional fee-for-service program. 
Utilization of secondary preventive medications was considered appropriate if patients 
ﬁlled at least 1 prescription for each of the recommended medications (angiotensin-
converting enzyme (ACE) inhibitors /angiotensin-receptor blockers, beta-blockers, and 
statins) in the 90 days after discharge. Logistic regression analysis was used to identify 
demographic and clinical predictors associated with the recommended utilization of 
secondary preventive medications. RESULTS: The ﬁnal study cohort consisted of 752 
patients discharged following hospitalization for AMI. The mean age of the cohort 
was 53±7.9 years and there were a higher proportion of females (59%) and whites 
(84.6%) in the study sample. Only 43.25% of the patients appropriately utilized all 
the recommended medications after AMI. Regression analysis indicated that use of 
percutaneous transluminal coronary angioplasty (PTCA) procedures during the hos-
pitalization (OR = 2.64; 95% CI:1.78–3.89); having a diagnosis of hyperlipidemia 
(OR = 1.71; 95% CI:1.17–2.51), hypertension (OR = 2.00; 95% CI:1.18–3.39) or 
asthma (OR = 0.56; 95% CI:0.37–0.87); and utilization of the recommended medica-
tions prior to hospitalization (OR = 2.42;95% CI:1.30–4.50) were signiﬁcant predic-
tors of appropriate utilization of secondary preventive medications. CONCLUSIONS: 
Post-AMI patients in a state Medicaid program had sub-optimal utilization of second-
ary preventive medications; however, the utilization rates were higher than in previous 
studies that primarily focused on an older cohort of patients.
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OBJECTIVES: The study evaluated medication utilization pattern of patients aged 50 
years and older with systolic hypertension (SH) in a primary care setting. Speciﬁc 
objectives were: 1) to assess the prevalence of comorbid conditions by patient demo-
graphics, and 2) to study the utilization of antihypertensive classes based on compel-
ling indications. METHODS: Retrospective analysis was conducted using GE 
Centricity electronic medical records (EMR) from a large primary care physician 
group. Patients with SH (ICD-9-CM 401.xx) with systolic blood pressure (SBP) 
>140 mmHg, diastolic blood pressure (DBP) <90 mmHg, 50 years and older, continu-
ously enrolled in the database and having 12 months pre- and post-index date observa-
tions were identiﬁed. Patients on dialysis were excluded from the study. Demographics, 
ofﬁce visits, clinical measures, compelling indications for antihypertensive treatment 
and comorbidities, drug regimens over a 2-year period were collected. Descriptive 
analysis was performed using SPSS version 17. RESULTS: A total of 22,074 patients 
had hypertension out of which 1,616 met the inclusion/exclusion criteria for SH. Mean 
age was 68.88±11.38 years; 59.03% females, and 78.4% had one or more compelling 
indications/comorbidities. Hyperlipidemia was the most prevalent comorbid condition 
(70.9%, n = 1,145), followed by diabetes (24.7%, n = 399) and coronary artery disease 
(15.6%, n = 252). A total of 16.4% of SH patients were on statins, followed by CCBs 
(16.2%) and ACEIs (15.3%). By compelling indications (top medication class), 18.8% 
patients with diabetes were taking CCBs, 16.9% patients with hyperlipidemia were 
taking CCBs, and 15.8% patients with CAD were taking ACEIs. CONCLUSIONS: 
Evidence from large clinical trials demonstrate that appropriate use of antihypertensive 
therapy in patients with SH and compelling indications reduces the incidences of 
stroke, myocardial infarction, and heart failure. Thus, it is important for physicians 
to follow the Seventh Joint National Committee (JNC 7) guidelines to improve quality 
of care and health outcomes in patients with SH.
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OBJECTIVES: Oral therapies that target nitric oxide signaling (sildenaﬁl) or endothe-
lin signaling (bosentan and ambrisentan) are used to treat pulmonary arterial hyper-
tension (PAH). We studied the treatment patterns, resource utilization, and costs 
associated with these three oral therapies in a US population of commercially insured 
patients. METHODS: This was a retrospective study using claims from a large health 
insurance database. Commercial and Medicare Advantage patients with claims indi-
cating PAH between January 2006 and December 2008 and whose ﬁrst PAH treat-
ment was for ambrisentan, bosentan, or sildenaﬁl were selected for study inclusion. 
PAH treatment patterns, PAH-related utilization, and PAH-related costs were assessed 
during a minimum 6 month follow-up period. RESULTS: A total of 727 patients were 
